Chuquiure-Valenzuela E

Language: Spanish
References: 37
Page: 121-126
PDF size: 108.45 Kb.

Text Extraction

No abstract

REFERENCES

1. DelRossi A, Cernaianu A, Botros S, et al. Prophylactic treatment of postperfusion bleeding using EACA. Chest 1989;96:27–30.

2. Johnson R, Thurer L, Kruskall S, et al. Comparison of two transfusion strategies after elective operations for myocardial revascularization. J Thorac Cardiovasc Surg 1992;104:307-314.

3. Surgenor DM, Wallace EL, Churchill WH, et al. Red cell transfusions in coronary artery by- pass surgery (DRGs 106 and 107). Transfusion 1992;32:458–464.

4. Unsworth-White MJ, Herriot A, Valencia O, et al. Resternotomy for bleeding after cardiac operation: a marker for increased morbidity and mortality. Ann Thorac Surg 1995;59:664–667.

5. Despotis GJ, Avidan MS, Hogue Jr CW. Mechanisms and attenuation of hemostatic activation during extracorporeal circulation. Ann Thorac Surg 2001;72:S1821–1831.

6. Hartstein G, Janssens M. Treatment of excessive mediastinal bleeding after cardiopulmonary bypass. Ann Thorac Surg 1996;62:1951–1954.

7. Bachmann F, McKenna R, Cole ER, et al. The hemostatic mechanism after open-heart surgery. I. Studies on plasma coagulation factors and fibrinolysis in 512 patients after extracorporeal circulation. J Thorac Cardiovasc Surg 1975;70:76–85.

8. Wasser MN, Houbiers JG, D’Amaro J, et al. The effect of fresh versus stored blood on post-operative bleeding after coronary bypass surgery: a prospective randomized study. Br J Haematol 1989;72:81–84.

9. Dacey LJ, Muñoz JJ, Baribeau YR, et al. Reexploration for hemorrhage following coronary artery bypass grafting: incidence and risk factors. Northern New England Cardiovascular Disease Study Group. Arch Surg 1998;133:442–447.

10. Utley JR, Wilde EF, Leyland SA, et al. Intraoperative blood transfusion is a major risk factor for coronary artery bypass grafting in women. Ann Thorac Surg 1995;60:570–574.

11. Moor E, Hamsten A, Blomback M, et al. Haemostatic factors and inhibitors and coronary artery bypass grafting: preoperative alterations and relations to graft occlusion. Thromb Haemost 1994;72:335–342.

12. Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation 1998;97:916–931.

13. Woodman RC, Harker LA. Bleeding complications associated with cardiopulmonary bypass. Blood 1990;76:1680–1697.

14. Warkentin TE, Moore JC, Anand SS, et al. Gastrointestinal bleeding, angiodysplasia, cardio-vascular disease, and acquired von Willebrand syndrome. Transfus Med Rev 2003;17:272–286.

15. Turner-Gomes SO, Andrew M, Coles J, et al. Abnormalities in von Willebrand factor and antithrombin III after cardiopulmonary bypass operations for congenital heart disease. J Thorac Cardiovasc Surg 1992;103:87–97.

16. Rawitscher RE, Jones JW, McCoy TA, et al. A prospective study of aspirin’s effect on red blood cell loss in cardiac surgery. J Cardiovasc Surg (Torino) 1991;32:1–7.

17. Reich DL, Patel GC, Vela-Cantos F, et al. Aspirin does not increase homologous blood requirements in elective coronary bypass surgery. Anesth Analg 1994;79:4–8.

18. Yende S, Wunderink RG. Effect of clopidogrel on bleeding after coronary artery bypass surgery. Crit Care Med 2001;29:2271–2275.

19. Bashein GF, Nessly ML, Rice AF, et al. Preoperative aspirin therapy and reoperation for bleeding after coronary artery bypass surgery. Arch Intern Med 1991;151:89–93.

20. Watson CJ, Deane AM, Doyle PT, et al. Identifiable factors in post-prostatectomy haemorrhage: the role of aspirin. Br J Urol 1990;66:85–87.

21. Merritt JC, Bhatt DL. The efficacy and safety of perioperative antiplatelet therapy. J Thromb Thrombolysis 2004;17:21–27.

22. Warkentin TE, Crowther MA. Reversing anticoagulants both old and new. Can J Anaesth 2002;49:S11–25.

23. Crowther MA, Berry LR, Monagle PT, et al. Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br J Haematol 2002;116:178–186.

24. Czer LS, Bateman TM, Gray RJ, et al. Treatment of severe platelet dysfunction and hemorrhage after cardiopulmonary bypass: reduction in blood product usage with desmopressin. J Am Coll Cardiol 1987;9:1139–1147.

25. Harker LA, Malpass TW, Branson HE, et al. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary Bypass: acquired transient platelet dysfunction associated with selective alpha-granule release. Blood 1980;56:824–834.

26. McKenna R, Bachmann F, Whittaker B, et al. The hemostatic mechanism after open-heart surgery. II. Frequency of abnormal platelet functions during and after extracorporeal circulation. J Thorac Cardiovasc Surg 1975;70:298–308.

27. Milam JD, Austin SF, Martin RF, et al. Alteration of coagulation and selected clinical chemistry parameters in patients undergoing open heart surgery without transfusions. Am J Clin Pathol 1981;76:155–162.

28. Brody JI, Pickering NJ, Fink GB. Concentrations of factor VIII-related antigen and factor XIII during open heart surgery. Transfusion 1986;26:478–480.

29. Whitlock RP, Crowther M, Blackall MH, et al. Warfarin cessation prior to cardiopulmonary bypass. Can J Cardiol 2004;20:63.

30. Jern C, Seeman-Lodding H, Biber B, et al. An experimental multiple-organ model for the study of regional net release/uptake rates of tissue-type plasminogen activator in the intact pig. Thromb Haemost 1997;78:1150–1156.

31. Valen G, Eriksson E, Risberg B, et al. Fibrinolysis during cardiac surgery: release of tissueplasminogen activator in arterial and coronary sinus blood. Eur J Cardiothorac Surg 1994;8:324–330.

32. Khuri SF, Valeri CR, Loscalzo J, et al. Heparin causes platelet dysfunction and induces fibrinolysis before cardiopulmonary bypass. Ann Thorac Surg 1995;60:1008–1014.

33. Tabuchi N, de Haan J, Boonstra PW, et al. Activation of fibrinolysis in the pericardial cavity during cardiopulmonary Bypass. J Thorac Cardiovasc Surg 1993;106:828–833.

34. Ellison N, Beatty CP, Blake DR, et al. Heparin rebound: studies in patients and volunteers. J Thorac Cardiovasc Surg 1974;67:723–9. [31] Salzman EW. Blood platelets and extracorporeal circulation. Transfusion 1963;80:274–277.

35. Panos A, Orrit X, Chevalley C, et al. Dramatic post-cardiotomy outcome, due to severe anaphylactic reaction to protamine. Eur J Cardiothorac Surg 2003;24:325–327.

36. O’Shaughnessy DF, Atterbury C, Bolton MP, et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004;126:11–28.

37. Mannucci PM. Hemostatic drugs. N Engl J Med 1998;339: 245–253.